

Chitosan-based nanosystem as pneumococcal vaccine delivery platform

Robla Álvarez, Sandra¹

Prasanna, Maruthi^{1,2}; Varela Calviño, Rubén³; Grandjean, Cyrille²; Csaba, Noemi¹.

1. Center for Research in Molecular Medicine and Chronic Diseases- CIMUS, University of Santiago de Compostela.

2. Unit Function & Protein Engineering, UMR CNRS 6286, University of Nantes, France.

3. Department of Biochemistry and Molecular Biology, University of Santiago de Compostela, Spain.

Sandra.robla@outlook.es

Abstract

Chitosan-based nanosystems have been described as interesting tools for antigen delivery, enhancing the immunogenicity of nasally administered vaccines [1]. The design of chitosan nanocapsules with the *Streptococcus pneumoniae* cell membrane protein PsaA (pneumococcal surface adhesin A), involved in adhesion and nasopharyngeal colonization processes [2] are proposed as an antigen-loaded vaccine delivery system candidate. These nanocarriers should reach to nasal subepithelial lymphoid follicles for their uptake by dendritic cells (DCs), for activation of specific T cells, producing an adaptive immune response against pneumonia [3].

Chitosan nanoparticles with thiol-maleimide conjugation between the polymer (chitosan) and the antigen (PsaA) were designed to enable surface presentation of PsaA for immune cell recognition. Spherical shaped particles, with size of 266 ± 32 nm, positive charge of $+30\pm 1$ mV and good stability profiles in simulated nasal fluids (up to 24 hours) were achieved. PsaA association rates were three times higher

compared to nanocapsules without covalent polymer-protein conjugation.

The maturation of pre-incubated immature DCs in the presence of antigen-conjugated nanocapsules, and subsequent studies of lymphocyte activation after this antigen presenting cells (APCs) presentation showed a higher capacity of nanocapsules to activate CD4 (CD4+/CD25+, 19% activation) and lower to CD8 T lymphocytes (CD8+/CD28+, 17% activation) compared to immature DCs (CD4+/CD25+ 16% and CD8+/CD28+, 18% activation). The evaluation of antigen-specific responses and cytokine profiles are currently underway to further evaluate the potential of these nanocapsules as vaccine delivery systems.

References

- [1] C. Prego, D. Torres, M. J. Alonso. *J. Drug Deliv. Sci. Technol.* 2006, 16, 5.
- [2] M. Prasanna *et al.* *Eur. J. Pharm. Sci.* 2018, 129.
- [3] N. Csaba, M. Garcia-Fuentes, M. J. Alonso. *Adv. Drug Deliv. Rev.* 2009, 61, 2.

Figures




Figure 1: TEM and SEM images of Chitosan-maleimide PsaA-SATA nanocapsules.